Patents by Inventor Govinda R. Bhisetti

Govinda R. Bhisetti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE
    Publication number: 20130012430
    Abstract: The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus.
    Type: Application
    Filed: June 27, 2012
    Publication date: January 10, 2013
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Roger D. Tung, Scott L. Harbeson, David D. Deininger, Mark A. Murcko, Govinda R. Bhisetti, Luc J. Farmer
  • Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease
    Patent number: 8314141
    Abstract: The present invention relates to Formula (II) compounds having the structure as well as to their use in methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases.
    Type: Grant
    Filed: February 14, 2008
    Date of Patent: November 20, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Roger D. Tung, Scott L. Harbeson, David D. Deininger, Mark A. Murcko, Govinda R. Bhisetti, Luc J. Farmer
  • NOVEL SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE
    Publication number: 20100210603
    Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
    Type: Application
    Filed: September 11, 2009
    Publication date: August 19, 2010
    Inventors: Roger D. Tung, Mark A. Murcko, Govinda R. Bhisetti
  • Sulfonamide inhibitors of aspartyl protease
    Patent number: 7608632
    Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
    Type: Grant
    Filed: April 19, 2006
    Date of Patent: October 27, 2009
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Roger D. Tung, Mark A. Murcko, Govinda R. Bhisetti
  • INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE
    Publication number: 20090143312
    Abstract: The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus.
    Type: Application
    Filed: February 14, 2008
    Publication date: June 4, 2009
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Roger D. Tung, Scott L. Harbeson, David D. Deininger, Mark A. Murcko, Govinda R. Bhisetti, Luc J. Farmer
  • Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease
    Patent number: 7388017
    Abstract: The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus.
    Type: Grant
    Filed: June 27, 2003
    Date of Patent: June 17, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Roger D Tung, Scott L Harbeson, David D Deininger, Mark A Murcko, Govinda R Bhisetti, Luc J Farmer
  • Sulfonamide inhibitors of aspartyl protease
    Patent number: 7321063
    Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
    Type: Grant
    Filed: February 24, 2004
    Date of Patent: January 22, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Roger D Tung, Mark A Murcko, Govinda R Bhisetti
  • Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease
    Publication number: 20040266731
    Abstract: The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus.
    Type: Application
    Filed: June 27, 2003
    Publication date: December 30, 2004
    Inventors: Roger D. Tung, Scott L. Harbeson, David D. Deininger, Mark A. Murcko, Govinda R. Bhisetti, Luc J. Farmer
  • Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease
    Patent number: 6617309
    Abstract: The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus.
    Type: Grant
    Filed: June 6, 2001
    Date of Patent: September 9, 2003
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Roger D Tung, Scott L. Harbeson, David D. Deininger, Mark A. Murcko, Govinda R. Bhisetti, Luc J. Farmer
  • Inhibitors of bace
    Publication number: 20030095958
    Abstract: The present invention relates to inhibitors of aspartic proteinases, particularly, BACE. The present invention also relates to compositions thereof and methods therewith for inhibiting BACE activity in a mammal, and for treating Alzheimer's Disease and other BACE-mediated diseases.
    Type: Application
    Filed: April 29, 2002
    Publication date: May 22, 2003
    Inventors: Govinda R. Bhisetti, Jeffrey O. Saunders, Mark A. Murcko, Christopher A. Lepre, Shawn D. Britt, Jon H. Come, David D. Deininger, Tianshang Wang
  • Novel sulfonamide inhibitors of aspartyl protease
    Publication number: 20030069222
    Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
    Type: Application
    Filed: March 8, 2002
    Publication date: April 10, 2003
    Applicant: Vertex Pharmaceuticals, Inc.
    Inventors: Roger D. Tung, Mark A. Murcko, Govinda R. Bhisetti
  • Novel sulfonamide inhibitors of aspartyl protease
    Publication number: 20030064977
    Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
    Type: Application
    Filed: March 8, 2002
    Publication date: April 3, 2003
    Applicant: Vertex Pharmaceuticals, Inc.
    Inventors: Roger D. Tung, Mark A. Murcko, Govinda R. Bhisetti
  • Sulfonamide inhibitors of aspartyl protease
    Patent number: 6372778
    Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 16, 2002
    Assignee: Vertex Pharmaceuticals, Incorporated
    Inventors: Roger D. Tung, Mark A. Murcko, Govinda R. Bhisetti
  • Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease
    Publication number: 20020032175
    Abstract: The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus.
    Type: Application
    Filed: June 6, 2001
    Publication date: March 14, 2002
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Roger D. Tung, Scott L. Harbeson, David D. Deininger, Mark A. Murcko, Govinda R. Bhisetti, Luc J. Farmer
  • Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease
    Patent number: 6265380
    Abstract: The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus.
    Type: Grant
    Filed: April 16, 1999
    Date of Patent: July 24, 2001
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Roger D. Tung, Scott L. Harbeson, David D. Deininger, Mark A. Murcko, Govinda R. Bhisetti, Luc J. Farmer
  • Sulfonamide inhibitors of aspartyl protease
    Patent number: 6004957
    Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
    Type: Grant
    Filed: July 22, 1998
    Date of Patent: December 21, 1999
    Assignee: Vertex Pharmaceuticals, Incorporated
    Inventors: Roger D. Tung, Mark A. Murcko, Govinda R. Bhisetti
  • Sulfonamide inhibitors of aspartyl protease
    Patent number: 5856353
    Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 5, 1999
    Assignee: Vertex Pharmaceuticals, Incorporated
    Inventors: Roger D. Tung, Mark A. Murcko, Govinda R. Bhisetti
  • Sulfonamide inhibitors of aspartyl protease
    Patent number: 5585397
    Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
    Type: Grant
    Filed: November 24, 1993
    Date of Patent: December 17, 1996
    Assignee: Vertex Pharmaceuticals, Incorporated
    Inventors: Roger D. Tung, Mark A. Murcko, Govinda R. Bhisetti